By Juliette Garnier
Sanofi will benefit a budget of 43.2 million dollars, 38.2 million euros to finance on development a vaccine against Zika . The French pharmaceutical group, world leader in vaccines, will get these funds from the US health authorities, he announced on Monday 26 September. The Biomedical Advanced Research and Development Authority (Barda), a body attached to the Secretary General of the Department of Health and Social Services, will be responsible for delivering the funds.
The contract between the pharmaceutical company and Barda until 2022 with an option that allows the French to benefit from an extension of 130.45 million dollars if the first test is considered positive. This funding should enable Sanofi and its vaccines unit, Sanofi Pasteur tested in phase II “purified vaccine containing inactivated virus Zika (ZPIV)” states the company in a statement.
ZPIV phase I trials are developed by the Walter Reed Army Institute of Research in collaboration with Sanofi Pasteur and the US Institute of Allergy and Infectious Diseases. “Given the devastating effects caused by this infectious disease, we are delighted that the US government has mobilized with us to develop a vaccine against Zika” welcomed David Loew, executive vice president of Sanofi, in a press release.
Public Health Emergency
Sanofi Pasteur “ pledged in February to develop a vaccine for prevent the Zika virus disease” shortly after the Organization World health said “infection represented a public health emergency,” statement recalled by the group, which generates 13% of its € 37 billion in revenue through vaccines.
Sanofi is not the only company involved in the race to develop a vaccine against Zika virus since its appearance in Brazil in 2015. Since then, 70 countries have reported the presence of this virus transmitted to humans by a mosquito bite and sexually, which, in pregnant women, can cause of microcephaly, insufficient development of brain child . Therefore, the sales potential of such a vaccine is huge. Especially since sexual transmission is considered more important than expected.
Among the candidates for a vaccine also included Japan’s Takeda. He received the American authorities a budget of $ 19.8 million for early September perform clinical human trials in the second half of 2017. The contract could to 312 million futures dollars.